• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Novartis

Siemens Healthineers acquires Novartis molecular imaging business

December 10, 2024 By Sean Whooley

Siemens Healthineers announced today that it completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis. The newly acquired unit is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. According to a news release, it will be known as “Advanced Accelerator Applications, a Siemens Healthineers company.” Reports first […]

Filed Under: Business/Financial News, Featured, Imaging, Mergers & Acquisitions, Oncology, Pharmaceutical, Radiosurgery/Radiation therapy Tagged With: Novartis, Siemens Healthineers

Report: Siemens Healthineers to buy Novartis’ molecular imaging business

August 26, 2024 By Sean Whooley

The Financial Times reports that Novartis received a binding offer from Siemens Healthineers to acquire its molecular imaging business. According to the report, Siemens Healthineers plans to pay approximately $224 million to buy the unit. It’s acquiring the diagnostic arm of Advanced Accelerator Operations, owned by Novartis. That business provides Fluorine-18 positron emission tomography, or […]

Filed Under: Business/Financial News, Imaging, Mergers & Acquisitions, Radiosurgery/Radiation therapy Tagged With: Novartis, Siemens Healthineers

Bausch + Lomb acquires XIIDRA eye drops, delivery system from Novartis in $2.5B deal

June 30, 2023 By Sean Whooley

Bausch + Lomb (NYSE:BLCO) announced today that it agreed to acquire XIIDRA non-steroid eye drops from Novartis. The company also acquired an investigational medicine and rights to a delivery device for treating dry eye disease (DED). AcuStream, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical […]

Filed Under: Business/Financial News, Drug-Device Combinations, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceutical, Vision Tagged With: Bausch + Lomb, Novartis

10 of the best pharma companies to work for

May 26, 2021 By Brian Buntz

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, Biogen, Eisai, Janssen, Johnson & Johnson, Merck, Moderna, Novartis, Pfizer, Roche, Roche Pharmaceuticals, Sage Therapeutics

Pharma’s top 20 R&D spenders in 2020

May 13, 2021 By Brian Buntz

The past year has been an unprecedented time for the pharmaceutical industry. On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.  While the […]

Filed Under: Featured, Pharmaceutical, Research & Development Tagged With: AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, H. Lundbeck, Incyte, Janssen, Merck, Novartis, Otsuka Holdings, Pfizer, Regeneron Pharmaceuticals, Roche, Roche Group, Roche Pharmaceuticals, Sumitomo Danippon Pharma, UCB, Vertex Pharmaceuticals

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Business/Financial News, Featured, Pharmaceutical Tagged With: AstraZeneca, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer, Pharma 50, Roche, Sanofi, Sinopharm

Tilak inks distro deal with Novartis for vision app

December 8, 2020 By Sean Whooley

Tilak Healthcare announced today that it entered into a framework agreement with Novartis (NYSE:NVS) to promote its OdySight remote monitoring app. Paris-based Tilak’s OdySight is a smartphone application designed to monitor and engage patients with age-related chronic eye diseases. The app is available by prescription and includes vision tests and puzzles to boost engagement while strengthening the patient-client […]

Filed Under: Business/Financial News, Optical/Ophthalmic, Patient Monitoring Tagged With: Novartis, Tilak Healthcare

Siemens, Novartis team up on MS drug development

September 21, 2020 By Nancy Crotti

Siemens Healthineers (ETR:SHL)  and Novartis (NYSE:NVS) have agreed to jointly design, develop and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline, the companies announced today. The first project will be a serum neurofilament light chain (NfL) immunoassay for patients with multiple sclerosis (MS) and other neurological diseases. Get the full story on our sister site, Drug […]

Filed Under: Business/Financial News, Distribution, Featured, Neurological, Pharmaceutical, Research & Development Tagged With: Novartis, Siemens Healthineers

Cala cites positive data in Trio tremor trial

August 17, 2020 By Tom Salemi

Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its  FDA-cleared Cala Trio device reported a reduction in hand tremors. The study — published in Tremor and Other Hyperkinetic Movements — enrolled 263 patients with essential tremor across 26 sites. Patients wore the Trio on […]

Filed Under: Bioelectronic Medicine, Clinical Trials, Featured Tagged With: Abbott, Cala Health, Intuitive Surgical, Novartis

The most innovative pharmaceutical agents of 2020

August 3, 2020 By Danielle Kirsh

The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, […]

Filed Under: Cardiovascular, Featured, Neurological, Oncology, Pharmaceutical Tagged With: AbbVie, Adlon Therapeutics, Advanced Accelerator Applications, Astellas Pharma, Bayer, Eli Lilly & Co., Galien Foundation, Genentech, Greenwich Biosciences, GW Pharmaceuticals, Janssen Biotech, Johnson & Johnson, Karyopharm Therapeutics, Medicines Development for Global Health, Merck, Novartis, Pfizer, Population Council, Purdue Pharma, Roche Group, Servier Pharmaceuticals, SIGA Technologies, Sobi, TB Alliance, Theravance Biopharma

MedTech 100 roundup: Stocks tick back up to open July

July 6, 2020 By Sean Whooley

After a solid start to July, the medtech industry continues to experience a stock market roller coaster amid the COVID-19 pandemic. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 84.25 points at the end of last week (July 3). That total represents a 2.9% increase from […]

Filed Under: Business/Financial News, Featured, Legal News, MassDevice Earnings Roundup, Mergers & Acquisitions, Research & Development, Wall Street Beat Tagged With: Abbott, alexionpharmaceuticals, coronavirus, COVID-19, DeviceTalks, DeviceTalks Weekly, MedTech 100 Index, Novartis, RTI Surgical, Smith & Nephew, Stryker, tandemdiabetes, Wright Medical

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 11
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy